Hepatitis C virus (HCV) chronic infections are a leading cause of advanced liver disease and hepatocellular carcinoma. The first-generation protease inhibitors were a major advancement in the standard of care for HCV patients, despite requiring use in prolonged combination regimens with pegylated interferon (peg-IFN) and ribavirin and characterized by suboptimal tolerability and efficacy. The launches of Gilead’s polymerase inhibitor Sovaldi (sofosbuvir) and Janssen’s second-wave protease inhibitor Olysio (simeprevir) have greatly improved the treatment options, allowing for shorter treatment durations, higher cure rates, and improved safety and tolerability profiles. Sovaldi is also the first product approved for use in peg-IFN-free regimens with ribavirin in certain HCV patients.
This report will track the trial, adoption and usage of Sovaldi and Olysio at 1-, 3-, 6- and 12-months following launch. The series will provide information on how these products fit into the treatment algorithm, impact current therapies, and change market dynamics. The reports also provide information on physician awareness of, and familiarity with, these products, their perceived clinical advantages and disadvantages, and physicians’ perspective on effectiveness of promotional messages and activities around Sovaldi and Olysio.
Questions Answered in This Report:
What is the extent of physicians’ awareness of, and interest in Sovaldi and Olysio? What are physician expectations for these products with respect to efficacy, safety and tolerability?
What proportion of gastroenterologists, hepatologists and infectious disease specialists have prescribed Sovaldi and Olysio, and when do non-prescribers expect to initiate trial usage?
What are the perceived clinical advantages and disadvantages of each product? What promotional messages are being delivered?
How does Sovaldi and Olysio fit in the treatment algorithm for chronic HCV infections? Which current treatment regimens will be displaced by Sovaldi and Olysio?
Which patient subpopulations are the likely recipients and candidates for Sovaldi, Olysio, or Sovaldi-based interferon-free therapy?
Approximately 50 gastroenterologists, 25 hepatologists, and 25 infectious disease specialists complete a 45-minute online quantitative survey with several open-ended questions for qualitative feedback. In addition, 10 surveyed specialists participate in a 30-minute qualitative interview.
Qualitative interviews with 15 physicians (divided equally by specialty) will also be conducted
To qualify, repondents must meet the following criteria:
- Manage a minimum of 50 patients with chronic HCV infections
- Have been in practice a minimum of 2 years and a maximum of 30 years
- Not a member of a national advisory board for either product / company
- More than 75% of professional time spent in clinical practice
- Final report in PowerPoint format
- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request
- Transcripts of qualitative interviews can be provided upon request
- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions in each wave
100 gastroenterologists, hepatolo-gists, and infectious disease specialists
Key Drugs Covered:
Sovaldi (sofosbuvir), Olysio (simeprevir), Incivek (telaprevir), Vic-trelis (boceprevir), Pegasys (peg-IFN-?-2a), PegIntron (peg-IFN-?-2b ), and ribavirin (generics)
Key Companies Mentioned:
- Johnson & Johnson / Janssen
DecisionBase®: Hepatitis C Virus, Genotype-3
Emerging Markets®: Hepatitis C Virus in Brazil
Patient Flow Model: Hepatitis C Virus
Pharmacor®: Hepatitis C Virus
Physician & Payer Forum®: Hepatitis C Virus (EU)
Physician & Payer Forum®: Hepatitis C Virus (US)
Physician & Payer Forum®: Hepatitis C Virus & PCPs (US)